Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis.

Takafumi Yanagisawa,Tatsushi Kawada,Keiichiro Mori,Sung Ryul Shim,Hadi Mostafaei,Reza Sari Motlagh,Fahad Quhal,Ekaterina Laukhtina,Markus von Deimling,Alberto Bianchi,Muhammad Majdoub,Maximilian Pallauf,Benjamin Pradere,Takahiro Kimura,Shahrokh F Shariat,Pawel Rajwa

BJU international（2023）

引用 0|浏览8

暂无评分

摘要

Among RCTs, novel systemic therapies seem to benefit the OS of patients with PCa irrespective of PS. Our findings suggest that worse PS should not discourage treatment intensification across all disease stages.

查看译文

关键词

performance status, Eastern Cooperative Oncology Group, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要